S100A9 and neoplasm: Analysis of the top 100 differentially expressed genes in tumor cells treated with the combination of nivolumab and ipilimumab showed the enrichment of a myeloid marker, S100A9, encoding S100 calcium-binding protein A9 (also known as myeloid-related protein 14 or MRP14), as one of the top-scoring hits (Supplementary Fig. S5).